Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.56 |
| ▸ | CNR2 | P34972 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437723 | 0.89 | GABRA2 (0.50) | CNR1CNR2GABRA2GABRB2CHRNA7 | |
| SCHEMBL6332827 | 0.89 | CNR1 (0.53) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL5339713 | 0.87 | CNR1 (0.50) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL4277527 | 0.87 | CNR1 (0.55) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL739526 | 0.87 | CNR1 (0.64) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL6342156 | 0.85 | CNR1 (0.49) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL6336715 | 0.83 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL8284682 | 0.81 | CNR1 (0.47) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL5370296 | 0.81 | CNR1 (0.47) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL5370292 | 0.81 | CNR1 (0.47) | CNR1CNR2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241788-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7230024-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1622909-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005061504-A1 | BICYCLIC PYRIDAZINONE CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005009974-A1 | IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026983-A1 | An imidazole compound containing an amine group is used in the treatment of diseases linked to the activation of the cannabinoid receptors in animals; eating disorders, weight loss, obesity, depression, bipolar disorders, psychoses, schizophrenia, substance abuse, alcoholism, Parkinson's disease, ADHD | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2004108728-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
| WO-2004094429-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KDM4E 3421/4885 |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885KDM4E 3489/4885 |
| US-20050026983-A1 | An imidazole compound containing an amine group is used in the treatment of diseases linked to the activation of the cannabinoid receptors in animals; eating disorders, weight loss, obesity, depression, bipolar disorders, psychoses, schizophrenia, substance abuse, alcoholism, Parkinson's disease, ADHD | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885KDM4E 1202/4885 |
| US-20040214855-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KDM4E 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.